These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 33986127)

  • 1. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
    Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
    Khaedir Y; Kartika R
    J Interferon Cytokine Res; 2021 Feb; 41(2):37-43. PubMed ID: 33621130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
    Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
    Liu B; Li M; Zhou Z; Guan X; Xiang Y
    J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 9. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
    Geng J; Wang F; Huang Z; Chen X; Wang Y
    Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
    Solimani F; Meier K; Ghoreschi K
    Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
    Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
    Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
    Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH).
    Díaz E; Amézaga Menéndez R; Vidal Cortés P; Escapa MG; Suberviola B; Serrano Lázaro A; Marcos Neira P; Quintana Díaz M; Catalán González M
    Med Intensiva (Engl Ed); 2021 Mar; 45(2):104-121. PubMed ID: 32854988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
    Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
    Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions.
    Shah M; Woo HG
    Mol Cells; 2021 Jun; 44(6):408-421. PubMed ID: 34059561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6: Relevance for immunopathology of SARS-CoV-2.
    Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
    Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
    Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
    Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.